Therapy Areas: Autoimmune
Lupin partners with Mylan to commercialise Enbrel (Etanercept) Biosimilar
28 June 2018 -

Pharma company Lupin Limited stated on Wednesday that it will commercialise its biosimilar to Enbrel (etanercept) in partnership with Mylan NV (NASDAQ:MYL).

Under the terms of the agreement, Mylan will commercialise Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.

According to the partnership, Enbrel is a TNF-inhibitor1 indicated to treat certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis as well as ankylosing spondylitis.

For the 12 months ending 31 December 2017, Enbrel had global brand sales of approximately USD11.6bn, according to IQVIA.

In February 2018, Lupin successfully completed its Etanercept biosimilar Phase 3 clinical trial. Lupin has filed the product with the European Medicines Agency and plans to file the product in other jurisdictions.

As part of the agreement, Lupin will receive an up-front payment of USD15m,potential commercial milestones as well as an equal share in net profits of Enbrel.